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1 
Summary 
1 Aminoglutethimide is a clinically available drug that suppresses steroid biosynthesis 
by inhibiting enzymes such as cytochrome P450scc and aromatase.  Because several 
members of neurosteroids regulate glutamate receptors, we investigated the effect of 
aminogluthetimide on cell death induced by over-activation of glutamate receptors in 
CNS neurons. 
2 Long-term pretreatment of organotypic cerebrocortical slice cultures with 
aminoglutethimide (100-1000 μM) for six days or over resulted in 
concentration-dependent suppression of neuronal cell death induced by NMDA.  
Aminoglutethimide (1000 μM) also inhibited neurotoxicity of AMPA and kainate, but 
not of ionomycin or staurosporine. 
3 The protective effect of aminoglutethimide against NMDA cytotoxicity was not 
mimicked by other steroid synthesis inhibitors including trilostane and exemestane, and 
was not reversed by concurrent application of steroids such as pregnenolone, estrone, 
17β-estradiol and estriol. 
4 In dissociated rat cerebrocortical cell cultures, long-term treatment with 
aminoglutethimide (10-1000 μM) attenuated NMDA receptor-mediated glutamate 
cytotoxicity but produced no significant effect on glutamate-induced increases in 
intracellular Ca2+. 
5 Brief as well as long-term pretreatment with aminoglutethimide (30-1000 μM) 
prevented NMDA receptor-dependent ischemic neuronal injury in organotypic 
cerebrocortical slice cultures, which was associated with suppression of glutamate 
2 
release during the ischemic insult. 
6 These results indicate that aminoglutethimide, irrelevant to its actions on 
neurosteroid synthesis, protects CNS neurons from excitotoxic and ischemic injuries.  
Development of aminoglutethimide analogs possessing neuroprotective properties may 
be of therapeutic value. 
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Abbreviations: [Ca2+]i, intracellular Ca2+ concentration; DIV, days in vitro; LDH, 
lactate dehydrogenase; MTT, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium 
bromide; PI, propidium iodide. 
3 
Introduction 
The term ‘excitotoxicity’ corresponds to damage of cells induced by aberrant activation 
of receptors for glutamate, the major excitatory neurotransmitter in CNS.  
Over-activation of glutamate receptors typically results from excessive release of 
glutamate from synaptic terminals and/or glial cells, as observed in seizure-induced 
neuronal damage and ischemic neuronal injury (Nishizawa, 2001; Holmes, 2002).  
Reduced capacity for glutamate uptake from the extracellular fluid represents another 
mechanism of glutamate receptor over-activation, as suggested in pathogenesis of 
amyotrophic lateral sclerosis (Maragakis & Rothstein, 2004).  In addition, neuronal 
damage by glutamate synergistically with other insults has been implicated in 
neurodegenerative disorders including Alzheimer’s, Parkinson’s and Huntington’s 
disease (Meldrum & Garthwaite 1990; Mattson, 2003).  In these ways, excitotoxicity 
plays a fundamental role in various pathological conditions in the brain. 
 Both neurons and glia can synthesize steroidal compounds called neurosteroids 
(Zwain & Yen, 1999), which exert various influences on brain function (Mellon & 
Griffin, 2002; Reddy, 2003).  Neurosteroids modulate activities of neurotransmitter 
receptors including ionotropic glutamate receptors (Wu et al., 1991; Irwin et al., 1994; 
Weaver et al., 2000), and several members of neurosteroids are shown either to suppress 
or to exacerbate excitotoxic neuronal injury.  For example, dehydroepiandrosterone 
and its sulfated derivative protect hippocampal neurons from excitotoxic insults by 
NMDA, AMPA or kainate (Kimonides et al., 1998; Kurata et al., 2004).  Pregnanolone 
sulfate, a metabolite of progesterone, inhibits NMDA-induced membrane current and 
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intracellular Ca2+ increase, and is neuroprotective against NMDA cytotoxicity 
(Park-Chung et al., 1997; Weaver et al., 1997; Shirakawa et al., 2002).  Moreover, 
Veiga et al. (2003) have demonstrated that pregnenolone and dehydroepiandrosterone, 
through aromatase-mediated conversion to estradiol, protect hippocampal hilar neurons 
against kainic acid cytotoxicity.  In contrast, pregnenolone sulfate positively modulates 
NMDA receptor channels and exacerbates NMDA-induced neuronal death (Weaver et 
al., 1998; Yaghoubi et al., 1998; Shirakawa et al., 2002). 
 These observations underscore the importance of neurosteroids in regulation of 
excitotoxicity-mediated neuronal damage.  However, the overall influence of 
biosynthesis of endogenous neurosteroids on excitotoxic injury remains unclear, 
because some neurosteroids are protective but others are deleterious to neuronal cells.  
Accordingly, we set out to examine the effect of aminoglutethimide (Figure 1a) on 
excitotoxicity-related neuronal injury.  Aminoglutethimide inhibits cytochrome 
P450scc with an apparent Ki value of 14 μM (Foster et al., 1983): cytochrome P450scc 
is an enzyme that catalyzes the first step of neurosteroid synthesis, namely, production 
of pregnenolone from cholesterol (Salhanick, 1982).  Aminoglutethimide also inhibits 
aromatase, an enzyme involved in production of estrogens, with an apparent Ki value of 
0.6 μM (Salhanick, 1982; Foster et al., 1983).  On the basis of these actions, clinical 
use of aminoglutethimide is approved in the United States for the treatment of 
hormone-dependent malignant tumors (Miller et al., 1987; Alshowaier et al., 1999).  
Here we report unexpected findings that aminoglutethimide protects cortical neurons 
from excitotoxic and ischemic injuries, probably through the mechanisms unrelated to 
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steroid biosynthesis. 
 
Methods 
Drugs and chemicals 
Unless otherwise indicated, drugs and chemicals were obtained from Nacalai Tesque 
(Kyoto, Japan).  DL-Aminoglutethimide, (+)-MK-801, ionomycin, estrone, 
17β-estradiol, estriol and pregnenolone were obtained from Sigma-Aldrich Chemicals 
(St. Louis, MO, USA).  Trilostane was purchased from Steraloids Inc. (Newport, RI, 
USA) and exemestane was from LKT laboratories (St. Paul, MN, USA).  (±)-AMPA 
was from Tocris Cookson (Bristol, UK) and staurosporine was from Calbiochem (San 
Diego, CA, USA).  Propidium iodide (PI) and KT5720 were from Wako Pure 
Chemicals (Osaka, Japan). 
 
Cortical slice cultures 
All experimental procedures were approved by our institutional animal experimentation 
committee, and animals were treated in accordance with the guidelines of the U.S. 
National Institutes of Health regarding the care and use of animals for experimental 
procedures.  Organotypic slice cultures were prepared with the procedures described 
previously (Shirakawa et al., 2002, 2005).  Briefly, we anesthetized postnatal day 2 or 
3 Wistar rats (from thirty-five mother rats in total) by chilling them in ice for 2-3 min, 
decapitated them, and removed the brain from the skull and cut it into two hemispheres.  
Each hemisphere was cut into coronal slices of 300 μm thickness with a tissue chopper 
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(Narishige, Tokyo, Japan), and six cerebrocortical slices (seven slices in some cases) at 
the rostro-caudal level containing the caudate putamen were transferred onto a 
Millicell-CM insert membrane (30 mm in diameter; Millipore, Bedford, MA, USA) in 
six-well plates.  Culture medium, consisting of 50% minimal essential 
medium/HEPES (GIBCO, Invitrogen Japan, Tokyo, Japan), 25% Hanks’ balanced salt 
solution (GIBCO) and 25% heat-inactivated horse serum (GIBCO) supplemented with 
6.5 mg ml−1 glucose and 2 mM glutamine, 100 U ml−1 penicillin G potassium and 100 
μg ml−1 streptomycin sulfate (GIBCO), was supplied at 0.7 ml per well.  Culture 
medium was replaced with fresh medium on the next day of culture preparation, and 
thereafter, every two days.  Slices were cultured in a humidified atmosphere of 5% 
CO2 and 95% air at 34°C.  From 10 days in vitro (DIV; 6 DIV in several experiments), 
cultures were maintained in serum-free medium consisting of 75% minimal essential 
medium/HEPES and 25% Hanks’ balanced salt solution supplemented with 6.5 mg ml−1 
glucose, 2 mM glutamine, 100 U ml−1 penicillin G potassium and 100 μg ml−1 
streptomycin sulfate. 
 
Cell death assay in slice cultures 
Slice cultures were treated with excitotoxins, ionomycin and staurosporine for 24 h at 
11 DIV with serum-free medium whose composition is described above.  Chemical 
ischemia was applied to cultures at 11 DIV by transfer of culture inserts to the plates 
containing the conditioning solution.  The conditioning solution was glucose-free 
Ringer’s buffer (124 mM NaCl, 4.9 mM KCl, 1.3 mM MgSO4, 2 mM CaCl2, 1.2 mM 
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KH2PO4 and 25.6 mM NaHCO3, pH 7.4) supplemented with 3 mM sodium azide and 10 
mM 2-deoxyglucose (Katsuki et al., 2005).  After ischemic treatment for 30-60 min, 
culture inserts were transferred to the plates containing serum-free culture medium and 
maintained for further 24 h. 
Cultures were fixed with 4% paraformaldehyde and 4% sucrose in 0.1 M 
phosphate buffer overnight, rinsed with distilled water twice and exposed to 0.1% 
toluidine blue solution for 15 min.  After rinse in distilled water, specimens were 
dehydrated by a graded series of ethanol and mounted with ENTELLAN Neu (Merck 
KGaA, Darmstadt, Germany).  Positively stained cells possessing round or oval cell 
bodies and clear nuclear boundaries were judged as viable neurons.  The maximal 
number of surviving neurons in an area of 80 × 90 μm2 within the parietal cortex of 
individual slices was counted. 
We also measured PI uptake into slices and lactate dehydrogenase (LDH) efflux to 
the culture medium.  PI (5 μg ml−1) was added to serum-free medium from 24 h before 
and during treatment with excitotoxins, ionomycin and staurosporine.  In the case of 
ischemia, PI (5 μg ml−1) was applied to slice cultures from 24 h before chemical 
ischemia, and also during 24 h of post-incubation.  Slices were observed with an 
inverted fluorescence microscope with a rhodamine filter set.  Fluorescence images 
were captured through a monochrome chilled CCD camera (C5985, Hamamatsu 
Photonics, Hamamatsu, Japan), and stored images were analyzed with NIH image 1.62 
software.  The average signal intensity in an area of 180 × 180 μm2 within the parietal 
cortex was obtained as the fluorescence value of each slice.  To reduce variability 
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among different sets of experiments, we normalized the fluorescent value with reference 
to that obtained with the ‘standard injury’.  The standard injury for slice cultures was 
induced by 24 h treatment with 200 μM NMDA, which nearly, but not exactly, equaled 
‘complete injury’.  In each set of experiments, one culture well received the standard 
injury, and the mean fluorescence value obtained from slices in this culture well was set 
to 100%.  Values obtained from slices in other wells that received various treatments 
were expressed as % of the standard injury.  We occasionally encountered slices 
exhibiting deteriorated appearance or robust PI fluorescence before application of 
insults.  These slices were excluded from cell death analysis. 
LDH activity in culture medium was measured with Cytotoxicity Detection LDH 
kit (Kyokuto Pharmaceutical Industrial, Tokyo, Japan).  Twenty-five μl of culture 
medium was mixed with 25 μl of LDH substrate mixture and 50 μl of 10 mM 
phosphate-buffered saline in a 96-well plate.  After incubation for 1 h at room 
temperature, the reaction was stopped by addition of 100 μl of 1 M HCl and the 
absorbance was measured at 570 nm.  Each value of absorbance was normalized with 
that in cultures receiving standard injury (200 μM NMDA for 24 h) as 100%. 
 
Quantification of glutamate released from slice cultures 
Amounts of glutamate released during chemical ischemia were measured with Amplex 
red glutamic acid/glutamate oxidase assay kit (Molecular Probes, Eugene, OR, USA) as 
described (Fujimoto et al., 2004).  After ischemic treatment, 50 μl of the ischemic 
conditioning solution in each well was collected and mixed with 50 μl of a reaction 
9 
buffer containing Amplex red, glutamate oxidase, glutamate pyruvate transaminase, 
alanine and horseradish peroxidase.  After incubation at 37°C, fluorescence of the 
reaction mixture emitted at 590 nm was measured with a fluorescence microplate reader 
(FlexStation; Molecular Devices, Sunnyvale, CA, USA) at an excitation wavelength of 
555 nm. 
 
Dissociated cortical culture and cell death assay 
Primary cultures of dissociated cortical neurons were prepared from the cerebral cortex 
of fetal Wistar rats (17-19 days of gestation) derived from sixteen mother rats in total, as 
described previously (Shirakawa et al., 2002).  Single cells mechanically dissociated 
from the whole cerebral cortex were seeded onto 48-well plates coated with 
polyethylenimine (for cell death assay) or onto glass coverslips coated with 
polyethylenimine (for Ca2+ measurement) at a density of 4.5 × 105 cells cml−2.  Cells 
were maintained at 37°C in a humidified 5% CO2 atmosphere in Eagle’s minimal 
essential medium (Nissui Pharmaceuticals, Tokyo, Japan) supplemented with glutamine 
(2 mM), glucose (11 mM in total), NaHCO3 (24 mM), HEPES (10 mM), and 10% 
heat-inactivated fetal bovine serum (1-7 DIV; JRH Biosciences, Lenexa, KS, USA) or 
10% heat-inactivated horse serum (8-12 DIV; JRH Biosciences).  Proliferation of 
non-neuronal cells was arrested by addition of 10 μM cytosine arabinoside at 6 DIV 
(Sigma-Aldrich Chemicals). 
At 11 DIV, glutamate was added to the medium for 24 h at a final concentration of 
300 μM, and cell death was evaluated by LDH release assay as mentioned above for 
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slice culture experiments, except that 15 μl of culture medium was mixed with 30 μl of 
the LDH substrate mixture and 60 μl of 10 mM phosphate-buffered saline.  Cultures 
treated with 10 mM glutamate for 24 h were used to determine the degree of the 
standard injury in each set of experiments.  Absorbance values were normalized with 
the absorbance in cultures that received standard injury as 100%. 
We also evaluated cell viability by 
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) assay.  Cultured 
cells were incubated in Eagle’s medium containing 0.5 mg ml−1 MTT for 2 h and then 
solubilized with isopropanol, and the absorbance at 595 nm was measured.  Viability 
was expressed as % of control, by setting the value of control cultures as 100% and the 
value of cultures receiving the standard injury (10 mM glutamate for 24 h) as 0%. 
 
Measurement of intracellular Ca2+ concentration 
Glutamate-induced increases in intracellular Ca2+ concentration ([Ca2+]i) were estimated 
with a Ca2+-sensitive fluorescent dye, fura-2 acetoxymethyl ester (Dojindo, Kumamoto, 
Japan), and a fluorescence imaging system (ARGUS-HiSCA, Hamamatsu Photonics, 
Shizuoka, Japan).  Dissociated cortical neurons at 11-12 DIV cultured on a 
polyethylenimine-coated glass coverslip were incubated in Krebs-Ringer buffer (137 
mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.5 mM CaCl2, 10 mM HEPES, 25 mM glucose, 
pH 7.4) containing 5 μM fura-2 acetoxymethyl ester and 0.01% cremophore EL 
(Sigma-Aldrich Chemicals) for 30 min at 37°C.  After post-incubation in fura-2-free 
Krebs-Ringer buffer for at least 30 min, the coverslip was transferred to a recording 
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chamber settled on the stage of an inverted fluorescence microscope.  Fura-2 
fluorescence obtained by excitation at wavelengths of 340 nm and 380 nm was recorded 
every 3 s at room temperature. 
 
Data presentation and statistical analysis 
Data are expressed as mean ± s.e.mean.  Statistical significance of difference was 
evaluated with one-way ANOVA followed by Student-Newman-Keuls’ test or Dunnett’s 
test.  Concerning values of glutamate release, two-tail paired t-test was used for 
evaluation of difference between the group that received ischemia alone and the group 
that received ischemia plus drug.  Probability values less than 5% were considered 
significant.  Values presented in a table and figures concerning Nissl staining (Figures 
1b, 2a and 3c) and PI uptake (Table 1, Figures 1c, 1e, 1f, 2b, 3a, 3b, 3d, 5a and 5b) in 
slice cultures as well as LDH release (Figures 4a) and MTT reduction (Figures 4b) in 
dissociated cultures are from a representative set of experiments.  Reproducibility of 
the results was confirmed in at least two (typically three to four) independent sets of 
experiments.  Values of LDH release in slice cultures (Figure 1d), glutamate-induced 
[Ca2+]i changes in dissociated cultures (Figure 4d) and glutamate release in slice 
cultures (Table 1, Figure 5c and 5d) are combined ones obtained from multiple sets of 
experiments. 
 
Results 
Aminoglutethimide protects cortical neurons in slice culture from excitotoxicity 
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Application of aminoglutethimide to cerebrocortical slice cultures from 1 DIV for 11 
days, at concentrations up to 1000 μM, did not cause any changes in the number of 
Nissl-stained viable cortical neurons, indicating that the drug itself was devoid of 
cytotoxic activity.  NMDA (20 μM) applied to control cultures at 11 DIV for 24 h 
caused a marked decrease in the number of surviving neurons, as assessed by Nissl 
staining.  This decrease in cell viability was accompanied by robust increases in PI 
fluorescence of slices and in the amount of LDH released into culture medium.  As 
shown in Figure 1b, continuous treatment with aminoglutethimide from 1 DIV 
prevented NMDA cytotoxicity in a concentration-dependent manner.  Judged from the 
number of Nissl-stained cells, significant neuroprotection was obtained with 
aminoglutethimide at concentrations of 300 μM and higher.  The protective effect was 
confirmed by measurement of PI fluorescence (Figure 1c) and LDH release (Figure 1d). 
 We next examined if aminoglutethimide could afford neuroprotection against insults 
other than NMDA.  Long-term treatment with 1000 μM aminoglutethimide inhibited 
neuronal injury induced by 24 h application of 40 μM AMPA, an excitotoxin acting on 
non-NMDA subtype of glutamate receptors.  The protective effect was confirmed by 
Nissl staining (data not shown) and PI uptake (Figure 1e).  Neuroprotective effect of 
1000 μM aminoglutethimide was also observed against cytotoxicity of 40 μM kainate, 
another non-NMDA receptor agonist (data not shown).  On the other hand, neuronal 
injury induced by 24 h application of a Ca2+ ionophore ionomycin (6 μM) was not 
affected by aminoglutethimide (Figure 1f).  Long-term treatment with 
aminoglutethimide was also without effect against cell death induced by 24 h 
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application of 6 μM staurosporine (data not shown). 
 To verify whether or not a prolonged treatment was required for neuroprotection, we 
varied the periods of application of aminoglutethimide (Figure 2).  Treatment with 
1000 μM aminoglutethimide for 6 days from 6 DIV suppressed neuronal injury induced 
by treatment with 20 μM NMDA at 11 DIV.  The degree of protection was comparable 
to that obtained by continuous treatment with 1000 μM aminoglutethimide from 1 DIV.  
In contrast, treatment with aminoglutethimide during the first half of the cultivation 
period, i.e., from 1 to 6 DIV, did not provide a significant effect.  Neither a shorter 
period of pretreatment from 10 DIV nor a simultaneous treatment at 11 DIV with 
aminoglutethimide suppressed NMDA cytotoxicity.  The results were confirmed by 
counting of Nissl-stained surviving cells (Figure 2a) and measurement of PI 
fluorescence (Figure 2b). 
 
Neuroprotective effect of aminoglutethimide is unrelated to inhibition of steroid 
synthesis 
To evaluate if the neuroprotective effect of aminoglutethimide is mediated by its effect 
on neurosteroid biosynthesis, we performed additional pharmacological examinations.  
First, two drugs that inhibit steroidogenic pathways were tested for their potential 
neuroprotective effects.  Trilostane competitively inhibits 3β-hydroxysteroid 
dehydrogenase, an enzyme involved in the conversion of pregnenolone, 
17-hydroxypregnenolone and dehydroepiandrosterone into progesterone, 
17-hydroxyprogesterone and Δ4-androsten-3,17-dione, respectively (Robel et al., 1995).  
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The IC50 value of trilostane on the enzyme activity has been reported to be 4.06 μM, 
when 1 μM pregnenolone is used as a substrate (Coirini et al., 2003).  Exemestane is a 
selective inhibitor of aromatase with a Ki value of 4.3 nM (Di Salle et al., 1994; Miller 
et al., 2003), therefore mimics part of the properties of aminoglutethimide as an enzyme 
inhibitor.  Trilostane (3-30 μM) and exemestane (1-10 μM) were applied to cortical 
slice cultures continuously from 1 DIV, and NMDA cytotoxicity was examined at 11 
DIV in the presence of these drugs.  Neither of these drugs produced a significant 
effect on cell death induced by 20 μM NMDA, as assessed by Nissl staining (data not 
shown) and PI fluorescence (Figure 3a, b).  We could not test the effect of these drugs 
at higher concentrations because of their cytotoxicity. 
 Second, we examined whether the neuroprotective effect of aminoglutethimide 
against NMDA cytotoxicity could be reversed by application of neurosteroids.  
Aminoglutethimide was applied to slice cultures from 6 DIV, simultaneously with 10 
μM of pregnenolone, estrone, 17β-estradiol or estriol.  To avoid any influences caused 
by steroidal compounds contained in serum, serum-free medium was used throughout 
the period of drug treatment.  In these settings, aminoglutethimide again prevented 
neuronal death induced by 24 h application of 20 μM NMDA.  However, neither of the 
steroids provided a significant influence on the neuroprotective effect of 
aminoglutethimide, as assessed by Nissl staining (Figure 3c) and PI fluorescence 
(Figure 3d).  These results do not support the proposal that neuroprotection by 
aminoglutethimide is mediated by depletion of neurosteroids from the cortical tissue. 
 Bastida et al. (2001) have reported that aminoglutethimide may act as an inhibitor of 
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protein kinase A.  Therefore, we examined the effect of KT5720, a selective protein 
kinase A inhibitor.  However, long-term treatment with 0.1-1 μM KT5720 did not 
produce a significant effect on NMDA cytotoxicity (data not shown). 
 
Effects of aminoglutethimide on glutamate cytotoxicity and glutamate-induced Ca2+ 
increase in dissociated cortical neurons 
A possible mechanism of neuroprotection by aminoglutethimide is that the drug may 
somehow inhibit Ca2+ influx through glutamate receptor-associated channels, thereby 
prevent intracellular Ca2+ concentration ([Ca2+]i) from reaching cytotoxic levels.  
Accordingly, we examined effect of aminoglutethimide on glutamate-induced increases 
in [Ca2+]i in cortical neurons.  For this purpose, we used dissociated cortical neurons 
instead of cortical slice cultures, because estimation of [Ca2+]i in slice culture 
preparations was difficult.  Before the experiments on [Ca2+]i, we did cytotoxicity 
experiments to confirm that aminoglutethimide was also neuroprotective in dissociated 
cortical cell cultures.  Application of 300 μM glutamate for 24 h resulted in neuronal 
death indicated by an increase in LDH release and a decrease in activity of MTT 
reduction.  Glutamate cytotoxicity under these conditions was abolished by 10 μM 
MK-801, an NMDA receptor antagonist (data not shown).  Continuous treatment of 
cortical neurons with aminoglutethimide (10 - 1000 μM) from 2 DIV to the end of the 
culture period resulted in a concentration-dependent inhibition of glutamate 
neurotoxicity, as assessed by LDH release assay (Figure 4a) and MTT assay (Figure 4b).  
The effect of aminoglutethimide was not reversed by concurrent application of 1 μM 
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pregnenolone (data not shown), suggesting again that inhibition of steroidogenesis was 
not responsible for neuroprotection. 
 Dissociated cortical neurons that received long-term treatment with 10-1000 μM 
aminoglutethimide were subjected to measurement of [Ca2+]i.  In sham-treated neurons, 
glutamate (300 μM) induced a robust [Ca2+]i increase that decayed gradually during 9 
min of observation period.  Neurons treated continuously with aminoglutethimide also 
responded to glutamate with an increase in [Ca2+]i (Figure 4c).  The peak levels of 
[Ca2+]i increase (Figure 4d) as well as the [Ca2+]i levels at 9 min after the onset of 
glutamate application (data not shown) did not significantly differ among different 
treatment groups.  Therefore, inhibition of Ca2+ influx is unlikely to mediate the 
neuroprotective effect of aminoglutethimide. 
 
Aminoglutethimide inhibits glutamate release and neuronal injury induced by ischemia 
in cortical slice culture 
Finally, we examined effects of aminoglutethimide on ischemia-induced neuronal injury.  
Simulated ischemia was achieved by incubation of cortical slice cultures with 
glucose-free Ringer’s buffer containing sodium azide and 2-deoxyglucose (Katsuki et 
al., 2005).  This treatment resulted in extracellular accumulation of glutamate during 
the treatment, and neuronal damage at 24 h after the treatment (Table 1).  Both 
consequences were increasingly apparent with longer periods of chemical ischemia.  In 
the following experiments, 45 min was adopted as the period of ischemic treatment.  
Application of 1 μM MK-801 during and after chemical ischemia almost completely 
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protected cortical neurons (data not shown).  Figure 5a shows that continuous 
treatment of cortical slice cultures with aminoglutethimide from 1 DIV suppressed 
ischemic neuronal injury.  The protective effect of aminoglutethimide was in a 
concentration-dependent manner, which was significant at or over 30 μM and was 
almost complete at 1000 μM.  Importantly, we found that prolonged treatment was not 
required for the protective effect.  Application of aminoglutethimide from 1 h before 
chemical ischemia also suppressed neuronal injury (Figure 5b).  The range of effective 
concentrations of aminoglutethimide in this setting (at or over 30 μM) was the same as 
that in long-term treatment. 
 Because glutamate cytotoxicity is central to ischemic neuronal injury, we examined 
if aminoglutethimide produced any influences on extracellular glutamate accumulation 
during ischemic insult.  We found that long-term treatment of slice cultures with 
aminoglutethimide (30-1000 μM) from 1 DIV markedly inhibited ischemia-induced 
glutamate accumulation in a concentration-dependent manner (Figure 5c).  The degree 
of inhibition of glutamate accumulation by various concentrations of aminoglutethimide 
paralleled the degree of neuroprotection.  Moreover, application of aminoglutethimide 
from 1 h before chemical ischemia was as effective as long-term treatment of the drug 
in suppressing glutamate accumulation (Figure 5d). 
 
Discussion 
The initial purpose of the present study was to verify potential roles of endogenous 
neurosteroids in regulation of excitotoxic neuronal injury in the cerebral cortex.  We 
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supposed that aminoglutethimide would be a useful pharmacological tool to address this 
issue, because the drug was expected to inhibit biosynthesis of neurosteroids by 
inhibiting cytochrome P450scc.  We found that aminoglutethimide produced potent 
neuroprotective effects in two paradigms of neuronal injury.  First, long-term treatment 
of cortical slice cultures with aminoglutethimide attenuated NMDA neurotoxicity.  The 
unexpected finding was that supplementation of various steroids did not reverse the 
neuroprotective effect of aminoglutethimide.  In particular, the ineffectiveness of 
pregnenolone, the immediate product of cytochrome P450scc, indicates that the 
observed effect of aminoglutethimide is not related to inhibition of neurosteroid 
biosynthesis.  Second, aminoglutethimide prevented ischemic neuronal injury.  
Although we did not examine the consequences of steroid supplementation in this 
paradigm, depletion of endogenous neurosteroids is unlikely to mediate neuroprotection 
by aminoglutethimide, because the drug effectively blocked ischemia-induced 
accumulation of extracellular glutamate and neuronal injury with only 1 h of 
pretreatment.  Aminoglutethimide has been shown to attenuate excitotoxicity in the 
retina, but in this case, the effect is mediated by reduction of de novo biosynthesis of 
pregnenolone sulfate (Guarneri et al., 1998).  Steroidogenesis-independent 
neuroprotective actions of aminoglutethimide are unprecedented findings of the present 
study. 
 Several days of treatment were required for the protective actions of 
aminoglutethimide against NMDA neurotoxicity.  In addition, long-term treatment 
with aminoglutethimide prevented neuronal death induced by excitotoxins including 
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NMDA, AMPA and kainate, but had no effect against other cytotoxic agents such as 
ionomycin and staurosporine.  Hence, a plausible mechanism of neuroprotection was 
that aminoglutethimide might decrease the number, or suppress the function, of 
ionotropic glutamate receptors, thereby attenuate excess Ca2+ entry during excitotoxic 
insults.  However, we did not observe a significant effect of aminoglutethimide on 
glutamate-induced increase in [Ca2+]i.  The results indicate that neuroprotective actions 
of aminoglutethimide may involve some cellular events downstream of glutamate 
receptor activation.  Screening of genes and proteins whose expression levels are 
modified by long-term treatment with aminoglutethimide may provide useful 
information concerning the molecular targets mediating neuroprotection. 
 Our results in the present study do not necessarily exclude the roles of endogenous 
neurosteroids in regulation of neuronal injury.  Substantial lines of evidence suggest 
that neurosteroids influence excitotoxic consequences in CNS neurons.  For example, 
dehydroepiandrosterone and its sulfate protect hippocampal neurons from excitotoxic 
insults (Kimonides et al., 1998; Kurata et al., 2004).  Pregnenolone sulfate augments, 
whereas pregnanolone sulfate inhibits, NMDA receptor-mediated Ca2+ influx and 
resultant cytotoxicity (Weaver et al., 1998; Shirakawa et al., 2002).  Because 
aminoglutethimide is likely to prevent excitotoxic injury through the mechanisms 
downstream of glutamate receptor activation, the effect of steroid depletion on neuronal 
death may well be occluded or masked by steroid-independent actions of 
aminoglutethimide.  Alternative methods like specific knockdown of cytochrome 
P450scc expression may be required to evaluate the net effects of depletion of 
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endogenous neurosteroids. 
 In contrast to the effect on NMDA cytotoxicity, the neuroprotective effect of 
aminoglutethimide against ischemic neuronal injury was evident after a brief period of 
pretreatment.  Because the degree of protection paralleled the decrease in the levels of 
glutamate accumulation during ischemic insult, we suggest that inhibition of aberrant 
release of glutamate is responsible for the effect of this drug against ischemic neuronal 
injury.  Detailed mechanisms of inhibition of glutamate release by aminoglutethimide 
remain an open question.  Various routes including exocytosis, reversed glutamate 
transport and efflux through volume-sensitive anion channels have been implicated in 
glutamate release from neurons and glia during ischemia (Nedergaard et al., 2002).  A 
nearly complete blockade of extracellular glutamate accumulation by 1000 μM 
aminoglutethimide, in spite of the presence of multiple routes of glutamate release, 
implies that the drug interferes with cellular events upstream of glutamate release, rather 
than individual release machineries. 
 In conclusion, we report here that aminoglutethimide exerted novel neuroprotective 
actions against excitotoxic and ischemic injuries.  The mechanisms of actions do not 
involve any known pharmacological properties of this drug and should be addressed in 
further investigations.  Aminoglutethimide has been used for therapies of 
hormone-dependent malignant tumors in the United States (Miller et al., 1987; 
Alshowaier et al., 1999).  Daily dose of aminoglutethimide is 250-1000 mg, and serum 
concentration of this drug in patients receiving 1000 mg dosing has been reported to be 
9.0 μg ml-1 (38.7 μM; Miller et al., 1987).  In addition, Unger et al. (1986) 
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demonstrated accumulation of [14C]-aminoglutethimide in the brain after systemic 
administration in rats.  Development of aminoglutethimide analogs that retain 
neuroprotective properties but are devoid of actions on steroidogenesis may be useful 
for therapies against various neurodegenerative disorders. 
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Figure Legends 
Figure 1  Continuous application of aminoglutethimide (AGT) protects neurons in 
cerebrocortical slice cultures from cytotoxicity of NMDA and AMPA.  (a) Chemical 
structure of AGT.  (b-d) AGT was applied to slice cultures at indicated concentrations 
from 1 DIV, throughout the entire period of cultivation.  NMDA (20 μM) was applied 
for 24 h at 11 DIV in the presence of AGT, and cellular injury at 12 DIV was 
determined by the number of Nissl-stained surviving neurons (b, n = 6-7 slices), 
intensity of PI fluorescence (c, n = 5-7 slices) and amount of LDH released into medium 
(d, n = 4 culture wells).  ‘Cont.’ means control cultures that did not receive drug 
treatment.  * P < 0.05, ** P < 0.01, *** P < 0.001 vs. NMDA alone.  (e) AGT was 
applied to slice cultures at indicated concentrations from 1 DIV.  AMPA (40 μM) was 
applied for 24 h at 11 DIV in the presence of AGT, and cellular injury at 12 DIV was 
determined by intensity of PI fluorescence (n = 4-6 slices).  * P < 0.05 vs. AMPA alone.  
(f) AGT was applied at indicated concentrations from 1 DIV, and ionomycin (6 μM) 
was applied for 24 h at 11 DIV in the presence of AGT.  Cellular injury at 12 DIV was 
determined by PI fluorescence (n = 5-6 slices).  In c-f, each value was normalized with 
that in slice cultures receiving the standard injury (200 μM NMDA for 24 h) as 100%. 
 
Figure 2  Long-term pretreatment is required for aminoglutethimide (AGT) to protect 
neurons from NMDA cytotoxicity.  AGT (1000 μM) was applied to cerebrocortical 
slice cultures for indicated periods (in DIV).  NMDA (20 μM) was applied for 24 h at 
11 DIV, and cellular injury at 12 DIV was determined by the number of Nissl-stained 
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surviving neurons (a, n = 5-6 slices) and intensity of PI fluorescence (b, n = 4-6 slices).  
In b, each value was normalized with that in slice cultures receiving the standard injury 
(200 μM NMDA for 24 h) as 100%.  *** P < 0.001 vs. NMDA alone. 
 
Figure 3  Neuroprotective effect of aminoglutethimide (AGT) is unrelated to steroid 
biosynthesis.  (a, b) Trilostane and exemestane do not protect cortical neurons from 
NMDA cytotoxicity. Trilostane (a) or exemestane (b) was continuously applied to 
cerebrocortical slice cultures at indicated concentrations from 1 DIV.  NMDA (20 μM) 
was applied for 24 h at 11 DIV in the presence of trilostane or exemestane, and cellular 
injury at 12 DIV was determined by intensity of PI fluorescence (n = 4-6 slices).  (c, d) 
Supplementation of various steroids does not reverse the neuroprotective effect of AGT.  
AGT (1000 μM) was applied to cerebrocortical slice cultures from 6 DIV in serum-free 
medium.  Steroids at 10 μM were applied concomitantly with AGT.  NMDA (20 μM) 
was applied for 24 h at 11 DIV in the presence of AGT and steroids, and cellular injury 
at 12 DIV was determined by the number of Nissl-stained surviving neurons (c, n = 6 
slices) and intensity of PI fluorescence (d, n = 5-6 slices).  In a, b and d, each value 
was normalized with that in slice cultures receiving the standard injury (200 μM NMDA 
for 24 h) as 100%.  *** P < 0.001 vs. NMDA alone. 
 
Figure 4  Long-term treatment with aminoglutethimide (AGT) protects dissociated 
cortical neurons from glutamate cytotoxicity, but has little effect on glutamate-induced 
increase in [Ca2+]i.  (a, b) Cultured cortical neurons were continuously treated with 
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AGT at indicated concentrations from 2 DIV.  Glutamate (300 μM) was applied for 24 
h at 11 DIV in the presence of AGT, and cell viability at 12 DIV was determined by 
amount of LDH released into medium (a, n = 6 coverslips) and cellular activity of MTT 
reduction (b, n = 6 coverslips).  * P < 0.05, ** P < 0.01 vs. glutamate alone.  Each 
value of absorbance in LDH release assay was normalized with that in dissociated 
cultures receiving the standard injury (10 mM glutamate for 24 h) as 100%.  The 
viability in MTT assay was expressed as % of control, by setting the value of control 
cultures as 100% and the value of cultures receiving the standard injury (10 mM 
glutamate for 24 h) as 0%.  (c) Glutamate-induced increase in [Ca2+]i was monitored 
by fura-2 fluorescence in neurons cultured under control conditions (left) and cultured 
in the continuous presence of 1000 μM AGT (right).  Glutamate (300 μM) was applied 
during the period indicated by a black bar.  Values represent the average value of 
fluorescence ratio obtained from 63 cells in one coverslip.  (d) Summary of data on 
glutamate-induced [Ca2+]i increase.  AGT at indicated concentrations was applied to 
cortical neurons from 2 DIV.  At 11-12 DIV, changes in [Ca2+]i induced by 300 μM 
glutamate were measured.  Values are mean + s.e.mean of the peak amplitude of 
[Ca2+]i responses obtained from 5-9 coverslips, the average of values of the control 
group being set at 100%. 
 
Figure 5  Aminoglutethimide (AGT) prevents neuronal injury and inhibits glutamate 
accumulation in cerebrocortical slice cultures that received chemical ischemia.  
Chemical ischemia was applied to slice cultures for 45 min at 11 DIV.  (a, b) Tissue 
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injury was measured by PI fluorescence after 24 h of post-incubation.  AGT at 
indicated concentrations was applied to slice cultures from 1 DIV (a) or from 1 h before 
ischemic treatment (b).  Each value was normalized with that in slice cultures 
receiving the standard injury (200 μM NMDA for 24 h) as 100%.  n = 6-28 slices.  (c, 
d) Glutamate concentrations in conditioning solution used for 45 min ischemia were 
measured.  AGT at indicated concentrations was applied to slice cultures continuously 
from 1 DIV (c) or from 1 h before ischemic treatment (d).  Values are expressed as % 
of glutamate concentration, with the value in cultures that received chemical ischemia 
alone at 100%.  n = 5-13 culture wells.  * P < 0.05, ** P < 0.01, *** P < 0.001 vs. 
chemical ischemia alone. 
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